AMGN SEC Filings

Amgen Inc. (AMGN) reported strong financial performance for the fiscal year ending December 31, 2025, with total product sales increasing by 10% to $35.1 billion. This growth was primarily driven by a 13% increase in volume, bolstered by key products such as Repatha, EVENITY, TEZSPIRE, and BLINCYTO. The company also saw significant progress in its pipeline, with multiple regulatory approvals and advancements in Phase 3 clinical studies. Amgen's strategic investments in manufacturing capacity expansion and R&D continue to support its long-term growth objectives. However, the company faces ongoing risks from patent expirations, increasing biosimilar competition, and evolving pricing and reimbursement pressures from government and commercial payers.

Amgen Inc. (AMGN) has filed an 8-K report on February 3, 2026, announcing its unaudited financial results for the fourth quarter and full year ended December 31, 2025. The report primarily furnishes a press release detailing these results, which includes a significant focus on non-GAAP financial measures. These non-GAAP measures, such as non-GAAP earnings per share, operating income, and margins, are presented to provide investors with a more comprehensive understanding of the company's ongoing business performance and facilitate comparisons across periods. The company explicitly states its belief that these non-GAAP metrics, alongside Free Cash Flow (FCF) and a debt leverage ratio, offer valuable supplementary insights. Amgen utilizes these measures internally for budgeting, financial planning, and performance evaluation. Key adjustments to GAAP figures include the exclusion of acquisition-related expenses, restructuring and cost savings initiatives, and certain other items like investment gains/losses and legal proceeding costs. Investors should note that these non-GAAP measures are not a substitute for GAAP reporting but are intended to enhance analytical perspectives.

Amgen Inc. (AMGN) announced on January 30, 2026, the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd., originally dated June 1, 2021. This termination is set to become effective upon receiving the necessary regulatory approvals, signaling a potential shift in Amgen's strategic partnerships and pipeline development. While the specific reasons for termination and the financial implications are not detailed in this filing, investors should monitor future communications for updates on how this development might impact Amgen's ongoing research and development efforts, particularly concerning any products or technologies covered under the terminated agreement. The agreement with Kyowa Kirin, if significant, could have implications for revenue streams, cost-sharing, or market access for certain therapeutic areas.

Amgen Inc. reported strong financial performance for the third quarter and first nine months of 2025, with total revenues increasing by 12% and 11% year-over-year, respectively, driven primarily by robust volume growth across its key products. Net income saw significant increases, up 14% for the quarter and a substantial 84% for the nine-month period, leading to a corresponding surge in diluted Earnings Per Share (EPS). The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues. Strategic investments in late-stage clinical programs continue, supported by strong operational cash flow generation. The company's balance sheet remains solid, though cash and cash equivalents decreased slightly from year-end 2024, largely due to significant debt repayment and dividend payments. Amgen continues to manage its debt effectively, reducing its overall debt principal. The company also highlighted ongoing legal matters, particularly the significant U.S. Tax Court case, which, while expected to be resolved no earlier than the second half of 2026, continues to be a point of attention. Despite potential regulatory headwinds and ongoing litigation, Amgen's operational performance and strategic investments indicate a positive outlook for future growth.

Amgen Inc. (AMGN) has filed a Form 8-K detailing its third quarter 2025 financial results, announced via a press release on November 4, 2025. The filing primarily furnishes the press release which includes the company's unaudited financial performance for the three and nine months ended September 30, 2025, as well as its financial position as of that date. Investors should note that Amgen is presenting both GAAP and non-GAAP financial measures, with a detailed reconciliation of these figures provided within the press release. The non-GAAP measures, including earnings per share, operating income, operating margin, tax rate, and operating expenses, are intended to offer a more insightful view of the company's ongoing operational performance by excluding certain items. These excluded items notably include acquisition-related expenses, costs associated with restructuring and cost-saving initiatives, and other non-ordinary course items such as investment gains/losses and legal proceeding costs. Amgen also highlights Free Cash Flow (FCF) as a key liquidity metric.

Amgen Inc. reported robust top-line growth for the second quarter and first half of 2025, with total revenues increasing by 9% and 10% respectively compared to the prior year periods. This growth was primarily driven by strong volume increases across key products, notably Repatha, EVENITY, BLINCYTO, and TEZSPIRE, which collectively offset modest net selling price declines. The company demonstrated significant profitability improvements, with net income soaring by 92% and 92% for the respective periods, and diluted EPS more than doubling year-over-year. This performance was supported by improved cost of sales as a percentage of revenue and well-managed selling, general, and administrative expenses, although R&D investments saw an increase. Despite the strong operational performance, investors should note the ongoing legal challenges, particularly the significant tax dispute with the IRS concerning past tax years, which continues through the judicial process. The company also faces ongoing patent litigations related to its key products like Repatha and Prolia/XGEVA, with several new biosimilar infringement lawsuits filed. While Amgen has a strong liquidity position with substantial cash and cash equivalents, its balance sheet reflects a notable decrease in cash from the prior year-end, largely due to significant debt repayments and dividend distributions. The company reiterated its commitment to capital allocation through debt reduction, dividends, and stock repurchases.

Amgen Inc. (AMGN) has filed an 8-K report on August 5, 2025, furnishing its Second Quarter 2025 earnings press release. The release, dated August 5, 2025, details the company's unaudited financial results for the period ending June 30, 2025, and its financial position as of that date. Investors should note that Amgen, in its reporting, provides both GAAP and a range of non-GAAP financial measures, including non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses. The company also reports Free Cash Flow (FCF). Amgen utilizes these non-GAAP measures to offer a more comprehensive view of its ongoing business operations and to facilitate comparisons across periods. Key adjustments from GAAP to non-GAAP figures include acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), costs associated with restructuring and cost savings initiatives, and other miscellaneous items like gains/losses on investments and legal proceeding impacts. These adjustments are made to present a clearer picture of operational performance and allow for better internal evaluation and external comparisons.

Amgen Inc. (AMGN) filed an 8-K report on May 27, 2025, detailing the outcomes of its annual meeting of stockholders held on May 22, 2025. The report primarily covers the election of directors, advisory votes on executive compensation, and the ratification of independent auditors. All 12 director nominees were overwhelmingly elected to serve a one-year term. Additionally, shareholders provided an advisory vote to approve executive compensation, which passed with a significant majority. Furthermore, the company's selection of Ernst & Young LLP as its independent registered public accountants for the fiscal year ending December 31, 2025, was ratified by stockholders. The voting results across all presented proposals indicate strong shareholder support for the company's governance and financial oversight practices. No other business was presented or voted upon during the meeting.

Amgen Inc. reported a significant turnaround in the first quarter of 2025, with net income swinging from a loss of $113 million in Q1 2024 to a profit of $1.73 billion in Q1 2025. This substantial improvement was driven by a robust increase in total revenues, which grew by 9% year-over-year to $8.15 billion, primarily fueled by an 11% rise in product sales to $7.87 billion. The company's operating income also saw a healthy increase of 19% to $1.18 billion, reflecting effective cost management despite a notable $800 million impairment charge related to Otezla. The balance sheet shows a decrease in cash and cash equivalents to $8.81 billion from $11.97 billion, alongside a reduction in total debt. The company continues to prioritize shareholder returns, declaring a quarterly dividend of $2.38 per share, underscoring its commitment to financial health and shareholder value. Investors should note the ongoing legal proceedings, particularly the significant U.S. tax litigation, which remains a key area of focus, although a decision is not expected until the second half of 2026.

Amgen Inc. (AMGN) has filed an 8-K report detailing its first-quarter 2025 financial results, announced on May 1, 2025. The report primarily furnishes the company's earnings press release, which includes a discussion of both GAAP and non-GAAP financial measures. Investors should note that Amgen provides non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses to offer a more comprehensive view of its ongoing business performance and facilitate comparisons across periods. Free Cash Flow (FCF) is also presented as a measure of liquidity. The company outlines the specific costs excluded from GAAP to arrive at these non-GAAP figures, including acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), restructuring and cost savings initiatives (severance, asset impairments), and other items outside the ordinary course of business (investment gains/losses, legal settlements). Amgen believes these adjustments provide a more meaningful evaluation of current and past operating performance by excluding items that can be inconsistent or non-recurring.

Amgen Inc. reported robust total revenue growth of 19% for the fiscal year 2024, reaching $33.42 billion. This growth was primarily driven by a 23% increase in product sales volume, boosted significantly by the acquisition of Horizon Therapeutics, which contributed $4.2 billion to sales. Key products like Repatha and TEZSPIRE showed strong performance, with sales increasing by 36% and 71% respectively. However, established products like ENBREL experienced a 10% decline in sales, reflecting ongoing competitive pressures and net selling price decreases. Amgen continued its strategic investment in R&D, with expenses increasing by 25% to $5.96 billion, indicating a strong commitment to pipeline development. The company also focused on debt reduction and returning capital to shareholders, with a 6% increase in its quarterly dividend.

Amgen Inc. (AMGN) filed an 8-K on February 4, 2025, primarily to furnish its Fourth Quarter and Full Year 2024 earnings press release. This filing provides investors with the company's unaudited financial results for the periods ending December 31, 2024. A key aspect of the release is its presentation of non-GAAP financial measures, which Amgen uses to offer a supplemental view of its performance, facilitating comparisons across periods by excluding items such as acquisition-related expenses, restructuring costs, and certain other irregular income and expenses. The company also presented Free Cash Flow (FCF) and a debt leverage ratio (debt to EBITDA) as additional metrics. Management believes these non-GAAP measures, alongside GAAP results, provide a more comprehensive understanding of Amgen's ongoing operational performance and liquidity. Investors should review the accompanying press release for detailed reconciliations of these non-GAAP figures to their GAAP equivalents and to understand the specific adjustments made, which include the treatment of acquired intangible assets and integration costs related to acquisitions.

Amgen Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $8.5 billion, up 23% year-over-year. This growth was primarily driven by a substantial 24% increase in total product sales, largely attributable to the successful integration of products acquired from Horizon Therapeutics. Key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE showed strong volume growth. Despite the revenue surge, net income saw a notable 64% increase to $2.83 billion, with diluted EPS rising to $5.22, reflecting improved operational efficiency and strategic asset contributions. However, operating expenses also grew significantly, up 32% in the quarter, largely due to higher amortization related to acquisition-related assets and increased R&D and SG&A spending. The company also reported a decrease in cash and cash equivalents to $9.0 billion from $10.9 billion at the end of the prior year, primarily due to debt repayments and dividend payments, though the company maintains ample liquidity. Investors should note the ongoing substantial legal and tax contingencies, particularly the IRS tax dispute, which continue to pose potential risks despite Amgen's belief in its strong legal standing.

Amgen Inc. (AMGN) has filed an 8-K report on October 30, 2024, to announce its unaudited third quarter and year-to-date financial results for 2024. The report primarily furnishes a press release detailing these results, which include both GAAP and non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP figures such as adjusted earnings per share, operating income, and free cash flow to provide a more transparent view of ongoing business performance and facilitate comparisons across periods, excluding items like acquisition-related expenses, restructuring costs, and certain investment gains/losses or debt-related charges. The press release itself, furnished as an exhibit, contains the detailed financial performance for the three and nine months ended September 30, 2024. The company emphasizes that these non-GAAP measures are supplementary and not a replacement for GAAP reporting. The rationale behind excluding certain items is to present a clearer picture of operational profitability by treating internally developed assets comparably to acquired ones and by removing volatile or non-recurring charges. Investors are encouraged to review the full press release for specific figures and the reconciliations between GAAP and non-GAAP metrics.

Amgen Inc. reported a notable increase in total revenues for the second quarter of 2024, reaching $8.4 billion, a 20% rise compared to the same period in the prior year. This growth was primarily driven by a significant 20% increase in product sales, largely attributable to the successful integration of Horizon Therapeutics and strong volume growth across key products. Despite the top-line expansion, operating income and net income experienced a decline due to a substantial increase in operating expenses, primarily driven by higher amortization related to the Horizon acquisition and increased R&D and SG&A expenses. Diluted EPS saw a corresponding decrease. The company's balance sheet shows a decrease in cash and cash equivalents to $9.3 billion from $10.9 billion at the end of 2023, alongside a reduction in total assets and stockholders' equity. Long-term debt also decreased. Amgen continued its commitment to capital allocation through dividend payments, though no shares were repurchased during the first half of 2024. The company remains focused on investing in innovation and managing its debt.

Amgen Inc. (AMGN) filed an 8-K on August 6, 2024, furnishing its Second Quarter 2024 earnings press release. The report details the company's financial results for the quarter ended June 30, 2024, and provides an update on its financial condition. A key focus of the filing is the presentation of non-GAAP financial measures, which Amgen uses to offer investors a clearer view of its ongoing business performance by excluding certain items. These excluded items primarily include acquisition-related expenses (such as amortization of acquired intangibles and fair value adjustments to acquired inventory), costs associated with restructuring and cost-saving initiatives, and other non-ordinary course of business items like gains/losses on equity investments and specific legal settlement-related items. The company believes these non-GAAP adjustments, alongside Free Cash Flow (FCF), facilitate better comparisons of performance across periods and enhance understanding of operational profitability and liquidity. Investors should review the press release (Exhibit 99.1) for the specific figures and detailed reconciliations between GAAP and non-GAAP results.

This 8-K filing from Amgen Inc. (AMGN) details the outcomes of its 2024 Annual Meeting of Stockholders held on May 31, 2024. The most significant information for investors pertains to the approval of the "Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan." This plan, now approved by stockholders, increases the number of shares available for issuance by over 31 million, clarifies dividend equivalent payouts, and incorporates updated change of control provisions to ensure unassumed awards will fully vest. Additionally, the filing confirms the election of all 12 director nominees for one-year terms and the advisory approval of executive compensation, indicating continued shareholder confidence in the current leadership and compensation structure. The ratification of Ernst & Young LLP as the independent registered public accountants for fiscal year 2024 also provides assurance regarding the company's financial reporting oversight. The appointment of Dr. Mary E. Klotman to the Corporate Responsibility and Compliance Committee and the Governance and Nominating Committee is a minor governance update. Overall, the filing reflects routine but important corporate governance actions, with the equity incentive plan amendment being the primary item of note for its potential impact on future equity-based compensation and share dilution.

Amgen Inc. reported a net loss of $113 million, or $(0.21) per share, for the first quarter of 2024, a significant shift from the $2.84 billion net income reported in the same period last year. This change was largely attributed to substantial non-cash charges, including unrealized losses on strategic equity investments and increased amortization and acquisition-related expenses stemming from the recent Horizon Therapeutics acquisition. Despite the net loss, total revenues grew by 22% year-over-year to $7.45 billion, driven by a 22% increase in product sales to $7.12 billion. The growth in product sales was primarily fueled by volume increases, with significant contributions from newly acquired Horizon products like TEPEZZA and KRYSTEXXA. Operationally, the company saw robust growth in key products such as Repatha (33% increase) and TEZSPIRE (80% increase), alongside contributions from the newly acquired Horizon portfolio. However, operating expenses surged by 54%, largely due to the impact of the Horizon acquisition, including higher amortization and acquisition-related costs, alongside increased R&D and SG&A expenses. The company also continues to navigate complex legal and tax matters, including an ongoing IRS tax dispute with potentially significant financial implications. Amgen's balance sheet remains solid, with substantial cash and cash equivalents, though debt levels remain elevated following the acquisition.

Amgen Inc. (AMGN) has filed an 8-K report on May 2, 2024, to announce its first-quarter 2024 financial results. The report primarily furnishes the company's earnings press release, which details both GAAP and non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP measures to provide a clearer view of its ongoing business operations and facilitate period-over-period comparisons. These non-GAAP adjustments exclude items such as acquisition-related expenses, restructuring costs, and certain other income/expense items deemed outside the ordinary course of business. The company also highlights Free Cash Flow (FCF) as a key liquidity metric. Investors are advised to review the full press release for detailed reconciliations between GAAP and non-GAAP figures.

Amgen Inc. reported strong performance in its 2023 Annual Report, highlighted by a significant increase in total product sales, primarily driven by volume growth in key products like Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO. The acquisition of Horizon Therapeutics plc in October 2023 for $27.8 billion was a major strategic move, bolstering Amgen's rare disease portfolio with the addition of TEPEZZA, KRYSTEXXA, and UPLIZNA. Despite a decline in sales for certain established products like ENBREL and Neulasta due to increased competition and pricing pressures, Amgen's overall revenue grew. The company is actively managing its pipeline, with promising developments in its Phase 3 programs and an increased focus on human genetics and innovative technologies. Amgen also continues its commitment to returning capital to shareholders through dividends and share repurchases, while navigating a complex regulatory and reimbursement landscape, including the ongoing tax dispute with the IRS.

Amgen Inc. (AMGN) filed an 8-K on February 6, 2024, to report its fourth-quarter and full-year 2023 financial results. The filing primarily furnished a press release announcing these results and detailing the company's financial performance. A key aspect of the report is Amgen's use of non-GAAP financial measures to provide investors with a more comprehensive understanding of its ongoing business operations and financial health. These non-GAAP measures, which exclude items like acquisition-related expenses, restructuring costs, and certain other non-operational items, are presented alongside GAAP figures to facilitate better comparisons across periods and enhance the evaluation of the company's underlying profitability and liquidity. Investors should note that Amgen's management believes these non-GAAP measures offer valuable insights by presenting a clearer view of the company's core business performance, free from the impact of significant one-time or irregular events. The report also highlights the reconciliation of these non-GAAP figures to their closest GAAP equivalents, emphasizing transparency in financial reporting. Furthermore, the company included metrics such as Free Cash Flow (FCF) and a debt leverage ratio, which are considered important indicators of liquidity and financial stability by management and are presented to aid investor analysis.

Amgen Inc. (AMGN) announced significant leadership changes within its Research and Development (R&D) and technology functions, effective December 18, 2023. Dr. David M. Reese is transitioning from his role as Executive Vice President, Research and Development, to a newly created position as Executive Vice President and Chief Technology Officer. In this new capacity, Dr. Reese will focus on leveraging technology and artificial intelligence (AI) to enhance Amgen's operations across the board. Concurrently, Amgen has appointed Dr. James Bradner as its new Executive Vice President, Research and Development, and Chief Scientific Officer. Dr. Bradner brings substantial experience from his previous role as President of the Novartis Institutes for BioMedical Research and membership in Novartis's Executive Committee. These strategic appointments signal Amgen's commitment to innovation, both in its core R&D endeavors and in the adoption of advanced technologies like AI to drive future growth and efficiency.

Amgen Inc. reported total revenues of $6.9 billion for the third quarter of 2023, a 4% increase compared to the same period last year, driven by a 5% rise in product sales to $6.5 billion. For the nine-month period, total revenues grew by 3% to $19.99 billion. Net income for the third quarter was $1.73 billion, a decrease of 19% year-over-year, resulting in diluted EPS of $3.22. However, for the nine-month period, net income surged by 21% to $5.95 billion, with diluted EPS of $11.06, demonstrating strong performance over the year-to-date. A significant event during the quarter was the completion of the acquisition of Horizon Therapeutics plc on October 6, 2023, for approximately $27.8 billion. This strategic move is expected to bolster Amgen's inflammation portfolio with key treatments for rare inflammatory diseases. The company also made progress in its pipeline, announcing positive Phase 2 data for tarlatamab in small cell lung cancer and positive Phase 3 data for LUMAKRAS/LUMYKRAS in colorectal cancer.

Amgen Inc. (AMGN) filed an 8-K on October 31, 2023, to report its unaudited financial results for the third quarter and first nine months of 2023, along with its financial position as of September 30, 2023. The report primarily includes a press release detailing these results and provides reconciliations for non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP metrics, such as non-GAAP earnings per share and operating income, to offer a more comparable view of ongoing business performance across periods, excluding items like acquisition-related expenses, restructuring costs, and certain other non-recurring items. The company also highlighted Free Cash Flow (FCF) as a key liquidity measure. Management believes these non-GAAP adjustments and FCF provide valuable insights into operational performance and financial health, facilitating a better understanding of the company's core business activities and its ability to generate cash. Investors are encouraged to review the provided press release for the detailed financial figures and the specific reconciliations between GAAP and non-GAAP measures.

Amgen Inc. announced the successful completion of its acquisition of Horizon Therapeutics plc on October 5, 2023. The acquisition, valued at approximately $26.7 billion, was settled through the payment of $116.50 in cash for each Horizon share. This move significantly expands Amgen's portfolio, particularly in the rare disease and inflammation areas, aligning with its strategic growth objectives. To finance a portion of this substantial acquisition and associated costs, Amgen drew down $4 billion under its Term Loan Credit Agreement on October 6, 2023. The completion of the acquisition also means Horizon shares will be delisted from the Nasdaq Global Select Market. Investors should note the strategic implications of this large-scale integration for Amgen's future revenue streams and market position.

Amgen Inc. announced a significant development in its acquisition of Horizon Therapeutics plc. On October 5, 2023, the High Court of Ireland sanctioned the scheme of arrangement for the acquisition. This regulatory approval is a critical step towards the completion of the transaction, which was initially announced on December 11, 2022. While the court's sanction is a major milestone, the acquisition is not yet fully complete. Amgen still needs to deliver a copy of the court order to the Registrar of Companies in Ireland. Investors should monitor this final procedural step, as it will pave the way for the official closing of the transaction and the integration of Horizon Therapeutics into Amgen's operations. This acquisition is expected to bolster Amgen's product portfolio and market presence.

Amgen Inc. (AMGN) has filed an 8-K report on September 11, 2023, providing an update on its proposed acquisition of Horizon Therapeutics plc. The key takeaway for investors is that the exclusivity period for the transaction has been extended. The "First Extended End Date" under the Transaction Agreement has been automatically pushed to the "Second Extended End Date," which is December 12, 2023. This extension suggests that both parties are continuing to work towards closing the deal, but also indicates that the process is taking longer than initially anticipated.

Amgen Inc. (AMGN) has provided an update on its previously announced acquisition of Horizon Therapeutics plc. The company has successfully resolved its legal challenge with the Federal Trade Commission (FTC) regarding the acquisition. The FTC's administrative lawsuit has been dismissed following a stipulated order agreement between Amgen, Horizon, and the FTC, which was approved by the U.S. District Court for the Northern District of Illinois. This effectively ends the FTC's legal opposition to the deal. Furthermore, the Irish High Court has scheduled a hearing for October 5, 2023, to review Horizon's application for sanctioning the proposed scheme of arrangement under Irish law. This is a crucial step in finalizing the acquisition under Irish corporate regulations. The resolution with the FTC and the upcoming Irish court hearing are positive developments, indicating progress towards the completion of Amgen's acquisition of Horizon.

Amgen Inc. (AMGN) filed an 8-K on September 1, 2023, to provide an update on its previously announced acquisition of Horizon Therapeutics plc. The key development is the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the FTC's administrative lawsuit challenging the acquisition. This agreement is a significant step towards closing the deal, removing a major regulatory hurdle. As a result of the consent order, Amgen and Horizon anticipate jointly filing to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court. They also expect to expedite the final approvals required under Irish law to complete the transaction. Investors should view this as positive news, indicating progress towards the closing of the Horizon acquisition.

Amgen Inc. reported solid financial results for the second quarter and first half of 2023, demonstrating revenue growth driven by key products like Prolia and Repatha. Total revenues for the quarter rose 6% to $6.99 billion, with product sales increasing by 6% to $6.68 billion. For the first six months, total revenues grew 2% to $13.09 billion, and product sales were up 4% to $12.53 billion. Net income for the quarter was $1.38 billion, a 5% increase year-over-year, translating to diluted EPS of $2.57, up 5%. The first half of the year saw a substantial 51% increase in net income to $4.22 billion, with diluted EPS soaring 53% to $7.86. This strong performance was bolstered by a significant increase in cash from operations and strategic debt issuances related to the proposed acquisition of Horizon Therapeutics, alongside a notable increase in long-term debt. The company continues to navigate potential regulatory challenges, particularly the FTC's lawsuit seeking to block the Horizon acquisition, with a preliminary injunction hearing scheduled. Amgen also remains engaged in ongoing patent litigation and tax disputes, though the company expresses confidence in its legal positions and financial resilience.

Amgen Inc. (AMGN) announced a key leadership transition in its finance department, effective August 14, 2023. Matthew C. Busch has been appointed as the new Vice President, Finance and Chief Accounting Officer (CAO), stepping into the role of principal accounting officer. This appointment is part of the company's leadership development initiatives, with the current CAO, Linda H. Louie, transitioning to Vice President, Finance, focusing on corporate financial planning and analysis. Mr. Busch has a long tenure at Amgen, having served in various finance and accounting roles since 2004, and most recently as Vice President, Finance. His compensation package for the CAO role includes a base salary of $450,000, an annual bonus target of 40% of his base salary, and an annual long-term incentive equity award valued at $500,000. This change appears to be a planned internal promotion aimed at fostering talent within the organization.

Amgen Inc. (AMGN) filed an 8-K on August 3, 2023, to furnish its second-quarter 2023 earnings press release. The release details the company's financial results for the period ending June 30, 2023, and provides a reconciliation of non-GAAP financial measures. Investors should note that Amgen emphasizes its use of non-GAAP figures to provide a clearer view of its ongoing business performance and liquidity, excluding items like acquisition-related expenses, restructuring costs, and certain investment/divestiture impacts. The company also presented adjusted figures for total revenues and product sales, accounting for foreign exchange impacts, to offer a better understanding of underlying sales trends. Free Cash Flow (FCF) is also highlighted as a key liquidity metric. While these non-GAAP measures are presented to supplement GAAP reporting and aid in comparative analysis, investors are reminded that they are not a substitute for GAAP measures and are not deemed 'filed' under Section 18 of the Exchange Act.

This 8-K filing from Amgen Inc. (AMGN) provides an update on the status of its proposed acquisition of Horizon Therapeutics plc. The primary focus is on the ongoing regulatory review by the U.S. Federal Trade Commission (FTC) and the legal proceedings stemming from the FTC's challenge to the acquisition. The filing details extensions to temporary restraining orders (TROs) that prevent Amgen from closing the deal until the court rules on the FTC's request for a preliminary injunction. Investors are informed that the court has scheduled an evidentiary hearing on the preliminary injunction for September 11, 2023. Based on this schedule, Amgen now anticipates the potential closing of the acquisition by mid-December, assuming the court denies the FTC's request. The company emphasizes that this timeline is contingent on the court's ruling and the satisfaction of other closing conditions.

Amgen Inc. (AMGN) filed an 8-K on May 22, 2023, detailing the results of its Annual Meeting of Stockholders held on May 19, 2023. The primary focus for investors is the overwhelmingly positive outcome of key shareholder votes, including the election of all 13 director nominees and the approval of executive compensation on an advisory basis. The company also ratified Ernst & Young LLP as its independent registered public accountants for the upcoming fiscal year. Significantly, shareholders voted overwhelmingly in favor of an annual advisory vote on executive compensation, aligning with the Board of Directors' recommendation. This indicates strong shareholder confidence in the company's governance and compensation practices. The consistent and high levels of support across all presented proposals suggest a stable and well-aligned shareholder base.

Amgen Inc. (AMGN) has filed an 8-K detailing an update regarding its proposed acquisition of Horizon Therapeutics plc. The U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block the acquisition, leading to a temporary restraining order (TRO) being issued by the court. This TRO prevents Amgen from closing the Horizon acquisition until at least September 15, 2023, or until the court makes a ruling on the FTC's request for a preliminary injunction. This development introduces significant uncertainty for investors regarding the completion of the Horizon acquisition, which was previously announced in December 2022. The legal challenge by the FTC is a critical hurdle, and the September 15th deadline set by the stipulated TRO provides a timeframe for further legal proceedings. Investors should monitor any updates on the court's decision regarding the preliminary injunction and Amgen's strategic responses.

Amgen Inc. (AMGN) has filed an 8-K to disclose that the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Amgen's proposed acquisition of Horizon Therapeutics plc. The FTC's action was initiated in the United States District Court for the Northern District of Illinois on May 16, 2023, aiming to prevent the completion of the acquisition. In response to the FTC's lawsuit, Amgen issued a press release on the same date, the content of which is included as an exhibit to this filing. Investors should closely monitor the legal proceedings and any further updates from Amgen or the FTC regarding this significant transaction, as the outcome will have a material impact on Amgen's future growth and strategic direction.

Amgen Inc. reported total revenues of $6.105 billion for the first quarter of 2023, a slight decrease from $6.238 billion in the same period of 2022. Despite the revenue dip, net income saw a significant increase, soaring to $2.841 billion ($5.28 diluted EPS) from $1.476 billion ($2.68 diluted EPS) in the prior year. This substantial earnings growth was largely driven by a substantial "Other income (expense), net" of $2.064 billion, primarily attributed to a significant unrealized gain from revaluing their investment in BeiGene. The company's strategic debt issuances totaling $24.0 billion in March 2023 were to finance the proposed acquisition of Horizon Therapeutics, which remains subject to regulatory review. Product sales showed modest growth of 2% to $5.846 billion, bolstered by strong performances from Prolia, Repatha, Nplate, and EVENITY. However, Enbrel and Otezla experienced declines. Operating expenses increased by 12% due to higher costs of sales, R&D investments, and expenses related to a restructuring plan. The company ended the quarter with a robust cash position of $31.6 billion, with a significant portion earmarked for the Horizon acquisition.

Amgen Inc. (AMGN) filed an 8-K on April 27, 2023, to report its First Quarter 2023 financial results. The filing primarily serves to furnish the company's earnings press release, which details both GAAP and non-GAAP financial measures. Investors should note that Amgen emphasizes its non-GAAP results to provide a clearer view of ongoing business performance, excluding items like acquisition-related expenses, restructuring costs, and certain investment and debt-related charges. The company utilizes these non-GAAP measures, alongside Free Cash Flow (FCF) and foreign exchange-adjusted revenue, to enhance understanding of operational performance and liquidity. While these adjustments aim to present a more consistent view of core operations, investors are reminded that these are supplementary and not a replacement for GAAP-based reporting. The details of these adjustments, including specific exclusions and reconciliations, are available in the furnished press release.

Amgen Inc. (AMGN) has announced a significant amendment and restatement of its revolving credit facility, increasing its total commitment to $4.0 billion. This facility, with an initial five-year term extendable by two additional one-year periods, is designed for general corporate purposes and serves as a liquidity backstop for its commercial paper program. The credit agreement includes provisions for an additional $1.25 billion increase at Amgen's request, subject to bank discretion and customary requirements. This strategic move enhances Amgen's financial flexibility and provides robust liquidity to support its operations and potential future needs. Furthermore, Amgen has fully terminated its previously established $28.5 billion bridge credit facility. This termination, effective March 9, 2023, follows the successful securing of substantial financing through senior notes, a term loan facility, and existing cash reserves. The company has determined that these combined liquidity sources are sufficient to finance the completion of its acquisition of Horizon Therapeutics plc, rendering the bridge facility unnecessary. The termination signifies a prudent management of its debt structure and a clear pathway to funding its strategic growth initiatives.

Amgen Inc. (AMGN) announced a significant debt issuance on March 2, 2023, raising approximately $23.77 billion in net proceeds through the sale of various senior notes with maturities ranging from 2025 to 2063. The primary purpose of this substantial capital raise is to fund the company's previously announced acquisition of Horizon Therapeutics plc. The issuance is not contingent on the completion of the acquisition, but the company has outlined a special mandatory redemption clause for most of the notes if the acquisition does not close by a specified date, with a redemption premium of 101%. Additionally, the company has permanently reduced its bridge credit facility, which was initially established to finance the Horizon acquisition, by an amount corresponding to the net proceeds from the senior notes offering, signaling a shift in financing strategy. This move effectively de-risks the acquisition financing to some extent by replacing a potentially more volatile credit facility with long-term debt. Investors should note the different interest rates and maturity dates across the series of notes issued, indicating a strategic approach to managing debt costs and maturity profiles. The senior notes rank equally with other senior unsecured debt and are subordinated to subsidiary obligations and secured debt. The significant proceeds raised and the associated debt issuance suggest Amgen is moving forward with its strategic growth plans, particularly the acquisition of Horizon Therapeutics, which is a key development for the company's future revenue streams and market position.

Amgen Inc. (AMGN) has filed an 8-K report detailing a significant debt offering completed on February 15, 2023. The company entered into an underwriting agreement to issue and sell a substantial aggregate principal amount of senior notes across various maturity dates, totaling approximately $23.4 billion. These new notes will rank equally with Amgen's other senior unsecured debt and will mature between 2025 and 2063, with coupon rates ranging from 5.150% to 5.750%. The proceeds from this offering are not explicitly stated in this filing but are typically used for general corporate purposes, potential acquisitions, or refinancing existing debt. Investors should note the closing date for this offering is expected to be March 2, 2023.

Amgen Inc. (AMGN) presented its 2022 annual report, highlighting robust product sales growth, particularly driven by Prolia, Repatha, and EVENITY. The company's total product sales increased by 2% to $24.8 billion, despite challenges like biosimilar competition and pricing pressures. A significant strategic move during the year was the announcement of the proposed acquisition of Horizon Therapeutics for approximately $27.8 billion, signaling Amgen's intent to expand its portfolio into rare, autoimmune, and inflammatory diseases. The company also advanced its pipeline, initiating Phase 3 trials for several key programs, including LUMAKRAS/LUMYKRAS for colorectal cancer and olpasiran for cardiovascular disease. Amgen continues to focus on innovation, manufacturing advancements, and global expansion, while navigating a complex regulatory and reimbursement landscape. The company maintained a strong financial position, with significant cash flow from operations and ongoing capital returns to shareholders through dividends and stock repurchases, though it also faces ongoing litigation regarding tax matters with the IRS.

Amgen Inc. (AMGN) filed an 8-K on January 31, 2023, detailing two key events. Firstly, the company amended its Share Purchase Agreement with BeiGene, Ltd., relinquishing its right to appoint a director to BeiGene's board. This change will shift Amgen's equity investment in BeiGene from the equity method to the fair value method of accounting, impacting financial reporting for this investment. Secondly, Amgen announced its fourth-quarter and full-year 2022 results via a press release furnished with the filing. The report also elaborates on Amgen's use and presentation of non-GAAP financial measures, including earnings per share, operating income, and revenue adjusted for foreign currency impacts. A significant update notes a modification to their non-GAAP policy starting Q1 2022, where upfront or milestone payments from licensing/collaboration agreements and asset acquisitions will no longer be excluded from non-GAAP measures, with prior periods being recast for comparability.

Amgen Inc. has entered into a new $4 billion Term Loan Credit Facility on December 22, 2022, comprised of an $2 billion 18-month tranche and a $2 billion 3-year tranche. This facility is specifically designed to finance the acquisition of Horizon Therapeutics plc, including transaction consideration, repayment of Horizon's existing debt, and associated fees and expenses. This financing action indicates a significant step forward in Amgen's strategic pursuit of Horizon Therapeutics. The new term loan will replace and reduce commitments under a previously established bridge credit facility. Investors should monitor the progress of the Horizon acquisition and its impact on Amgen's leverage and future cash flow, as the loan terms include covenants related to interest coverage ratios and debt limitations.

Amgen Inc. has announced a significant definitive agreement to acquire Horizon Therapeutics plc for $116.50 per share in cash. This acquisition, valued at approximately $28 billion based on the offer price, will be executed via a court-sanctioned scheme of arrangement under Irish law, with the potential to be structured as a takeover offer. The transaction has been unanimously recommended by Horizon's board of directors and is expected to close in the first half of 2023, subject to customary closing conditions including regulatory approvals in the U.S., Austria, Germany, and foreign investment clearances in France, Germany, Denmark, and Italy. To finance this substantial acquisition, Amgen has secured a $28.5 billion bridge credit facility. This facility is intended to cover the cash consideration for Horizon's shares, refinance Horizon's existing debt, and manage associated fees and expenses. The agreement includes standard representations, warranties, and covenants, with provisions for termination under specific circumstances, including potential termination fees. This move represents a major strategic expansion for Amgen, aiming to integrate Horizon's portfolio and operations.

Amgen Inc. filed an 8-K on December 2, 2022, primarily to disclose an announcement made on the same date pursuant to Irish Takeover Panel rules. This filing is a regulatory disclosure and does not contain new financial statements or detailed operational updates. The key takeaway for investors is that Amgen is adhering to specific disclosure requirements in Ireland, likely related to ongoing corporate activities or potential transactions governed by Irish regulations. Investors should note that the content of this announcement (Exhibit 99.1) is not considered 'filed' for the purposes of Section 18 of the Exchange Act, meaning Amgen is not subject to liability for omissions or misstatements within it under that specific section. However, it is incorporated by reference, suggesting its relevance to the ongoing corporate narrative. Any significant implications for investors will be detailed within the actual announcement, which would need to be reviewed separately.

Amgen Inc. reported solid financial results for the third quarter and first nine months of 2022, demonstrating resilience despite a challenging macroeconomic environment. Total revenues for the nine months increased by 2% year-over-year to $19.48 billion, driven by product sales growth and increased other revenues. Net income also saw a significant increase of 24% for the same period, reaching $4.94 billion, with diluted Earnings Per Share (EPS) rising to $9.11. The company's operating income showed substantial growth, up 38% for the nine-month period, reflecting effective cost management and operational efficiency. The company continued its strategic capital allocation through robust share repurchases and dividend payments, underscoring its commitment to returning value to shareholders. Amgen also made significant progress on its pipeline, highlighted by positive trial results for LUMAKRAS/LUMYKRAS. The recent acquisition of ChemoCentryx, Inc. for approximately $3.7 billion is expected to further enhance its therapeutic offerings in autoimmune diseases, inflammatory disorders, and cancer, positioning the company for future growth.

Amgen Inc. (AMGN) filed an 8-K on November 3, 2022, primarily to report its third-quarter 2022 financial results. The filing includes a press release detailing the company's financial performance for the three and nine months ended September 30, 2022. A significant portion of the 8-K is dedicated to explaining Amgen's use of non-GAAP financial measures, including non-GAAP earnings per share, operating income, and net income. The company utilizes these non-GAAP metrics to provide investors with a more comprehensive understanding of its ongoing business operations, excluding items such as acquisition-related expenses, costs from cost-saving initiatives, and certain investment or legal settlement impacts. Additionally, Amgen clarified its updated non-GAAP policy implemented in the first quarter of 2022, which no longer excludes upfront or milestone payments for licensing or collaboration agreements, and asset acquisitions of pre-approval/in-process R&D. While this change does not affect the third-quarter 2022 results, it does impact previously reported third-quarter 2021 non-GAAP results, which have been recast for comparability. Investors should review the provided reconciliations to understand the differences between GAAP and non-GAAP figures.

Amgen Inc. (AMGN) has officially announced the completion of its acquisition of ChemoCentryx, Inc. as of October 19, 2022. This strategic move, detailed in a press release filed on October 20, 2022, signifies a significant expansion of Amgen's capabilities, particularly in the area of inflammatory and autoimmune diseases, which was a key focus for ChemoCentryx. Investors should note that this acquisition is expected to bolster Amgen's pipeline and market presence in these therapeutic areas.

Amgen Inc. (AMGN) has filed an 8-K report detailing the issuance and sale of $3 billion in senior notes across three tranches: $1.25 billion in 4.050% Senior Notes due 2029, $750 million in 4.200% Senior Notes due 2033, and $1 billion in 4.875% Senior Notes due 2053. The net proceeds from this offering are approximately $2.976 billion. This significant debt issuance suggests Amgen is likely funding strategic initiatives, such as potential acquisitions, research and development expansion, or general corporate purposes. Investors should monitor how these proceeds are deployed to assess their impact on future growth and profitability. The terms of these notes include semi-annual interest payments and maturity dates ranging from 2029 to 2053. A notable feature is the provision for noteholders to require Amgen to repurchase the notes at 101% of the principal amount plus accrued interest in the event of a change in control triggering event. The new notes rank equally with other senior unsecured debt and are effectively subordinated to subsidiary obligations and senior to subordinated debt.